BioPorto announces the publication of urinary NGAL reference ranges in healthy adult and pediatric individuals
MWN-AI** Summary
BioPorto, a Copenhagen-based in vitro diagnostics company, announced on January 23, 2025, the publication of new reference ranges for urinary Neutrophil Gelatinase-Associated Lipocalin (NGAL) in healthy adults and children. This study, published in the peer-reviewed journal *Diagnostics*, presents a critical advancement in Acute Kidney Injury (AKI) detection, allowing clinicians to better evaluate NGAL levels in patients. By establishing standardized reference intervals, the study aims to facilitate the implementation of NGAL assays in clinical settings, thereby enhancing patient management.
This comprehensive research included a diverse cohort of 629 participants, ranging from three months to over 65 years old, marking it as the largest study of its kind to date. According to Tabari Baker, PhD, Vice President of Global Medical Affairs at BioPorto, these reference intervals are essential for laboratory scientists and clinicians working with at-risk patients. The study complements previous findings from BioPorto’s GUIDANCE clinical validation trial, solidifying the company’s commitment to improving AKI detection and patient outcomes.
The publication serves as a foundational resource for laboratories utilizing BioPorto’s NGAL assays, allowing for the effective comparison of NGAL levels in healthy populations. BioPorto’s primary goal is to assist clinicians in the early identification of AKI, a condition characterized by sudden kidney failure or damage that can lead to significant health complications. The signature NGAL tests from BioPorto, which already have CE mark registrations in several countries, establish a promising pathway for improving clinical outcomes through proactive kidney management.
For more detailed information, interested parties can access the publication and the company’s additional resources through their website.
MWN-AI** Analysis
The recent announcement from BioPorto regarding the publication of urinary NGAL reference ranges marks a significant advancement in the field of diagnostics for Acute Kidney Injury (AKI). As an in vitro diagnostics company, BioPorto’s commitment to enhancing early detection and management of AKI is reinforced by this comprehensive study involving 629 individuals across a wide age spectrum. This publication not only establishes a critical baseline for NGAL levels among healthy populations but also enhances the utility and accuracy of the NGAL immunoassay in clinical settings.
For investors, this development is worth close attention. The publication serves as a strong validation of BioPorto's diagnostic tools, providing a competitive edge as more laboratories begin to implement NGAL assays. The increasing prevalence and awareness of AKI—especially in acute care settings—coupled with regulatory approvals such as the CE mark further solidify BioPorto's market position and potential for growth.
Given the growing demand for effective biomarkers in the diagnosis and management of kidney-related conditions, BioPorto is well-positioned to capitalize on this market. Investors should consider the implications of this publication as it may drive increased adoption of BioPorto’s NGAL tests and boost its market share.
Additionally, the strategic combination of robust clinical validation trials and the recent publication enhances credibility with healthcare providers, potentially leading to increased sales and revenue streams. As healthcare continues to shift towards preventive and personalized medicine, BioPorto’s innovative solutions appear poised for sustainable growth.
In conclusion, for investors seeking opportunities in the biotech sector, particularly in diagnostics, BioPorto’s advancements in NGAL testing warrant close consideration as the company navigates this promising landscape, setting the foundation for long-term value creation.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
News Release
January 23, 2025
BioPorto announces the publication of urinary NGAL reference ranges in healthy adult and pediatric individuals
COPENHAGEN, DENMARK, January 23, 2025 (GLOBE NEWSWIRE) – BioPorto, an in vitro diagnostics company focused on empowering the early detection of Acute Kidney Injury (AKI), announced today their publication of reference intervals using BioPorto’s NGAL immunoassay in healthy adult and pediatric individuals. The study was published in Diagnostics , an international, open-access, peer-reviewed journal and provides clinicians with a standardized comparison to evaluate NGAL levels ensuring broad clinical applicability in their patients.
The publication of the reference range study results will be used by laboratories implementing NGAL assays from BioPorto as a baseline of healthy patient populations, a required step for laboratories to implement clinical tests. These findings address the critical gaps in kidney injury management and ultimately can help with earlier identification of AKI with the use of biomarkers.
This BioPorto study is the largest comprehensive study to date of 629 patients with ages ranging from three months to older than 65 years. Tabari Baker, PhD, Vice President of Global Medical Affairs states, “NGAL reference intervals in healthy populations are an essential tool for laboratory scientists and clinicians to use in patients at risk of acute kidney injury. This publication, in conjunction with our recently published GUIDANCE clinical validation trial, demonstrates BioPorto’s commitment to developing clinical tools for improving patient outcomes.”
The publication can be found here: Determination of Urinary Neutrophil Gelatinase-Associated Lipocalin (uNGAL) Reference Intervals in Healthy Adult and Pediatric Individuals Using a Particle-Enhanced Turbidimetric Immunoassay .
To subscribe to investor news from BioPorto, please sign up at https://bioporto.com/investor-contact/
For product information visit bioporto.com or connect with a team member at https://bioporto.com/schedule-a-meeting/
For further information
Jennifer Zonderman, BioPorto, +1 617 694 2918, jmz@bioporto.com
Niels Hoy Nielsen, +45 4529 0000, investor@bioporto.com
About Acute Kidney Injury
Acute kidney injury is a sudden episode of kidney failure or kidney damage that happens within a few hours or a few days. AKI causes a build-up of waste products in blood and makes it difficult for kidneys to maintain the proper balance of bodily fluids. AKI can also affect other organs such as the brain, heart, and lungs and is common in patients who are in hospital intensive care units. For more information about AKI please visit: https://bioporto.com/aki/ .
About BioPorto
BioPorto is an in vitro diagnostics company focused on saving lives and improving the quality of life with actionable biomarkers – tools designed to help clinicians make changes in patient management. The Company uses its expertise in antibodies and assay development, as well as its platform for assay development, to create a pipeline of novel and compelling products that focus on conditions where there is significant unmet medical need, and where the Company’s tests can help improve clinical and economic outcomes for patients, providers, and the healthcare ecosystem.
The Company’s flagship products are based on the NGAL biomarker and designed to aid in the risk assessment and diagnosis of Acute Kidney Injury, a common clinical syndrome that can have severe consequences, including significant morbidity and mortality, if not identified and treated early. With the aid of NGAL levels which rise in relation to kidney injury, physicians can identify patients potentially at risk of AKI more rapidly than is possible with current standard of care measurements, enabling earlier intervention and more tailored patient management strategies. The Company markets NGAL tests under applicable registrations including CE mark in several countries worldwide.
BioPorto has facilities in Copenhagen, Denmark and Boston, MA, USA. The shares of BioPorto A/S are listed on the Nasdaq Copenhagen stock exchange. For more information visit http://www.bioporto.com .
FAQ**
How will the publication of urinary NGAL reference ranges by BioPorto AS - Ordinary Shares - Class B THOXF influence the adoption of NGAL assays in clinical laboratories?
What are the potential implications of the comprehensive study results for BioPorto AS - Ordinary Shares - Class B THOXF in terms of market expansion and increased demand for their diagnostic products?
How does BioPorto AS - Ordinary Shares - Class B THOXF plan to leverage the findings from this publication to enhance their position in the acute kidney injury diagnostic market?
In what ways could the new reference ranges established by BioPorto AS - Ordinary Shares - Class B THOXF improve clinical outcomes in the management of patients at risk for acute kidney injury?
**MWN-AI FAQ is based on asking OpenAI questions about Bioporto AS - Ordinary Shares - Class B (OTC: THOXF).
NASDAQ: THOXF
THOXF Trading
100.0% G/L:
$0.288 Last:
10,332 Volume:
$0 Open:
